Clinical pharmacogenomics: Opportunities and challenges at point of care

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 33-35

  Scott, S A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; WARFARIN;

ALLELE; ANTICOAGULANT THERAPY; ARTICLE; EFFECT SIZE; GENOTYPE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; POINT OF CARE TESTING; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; GENETIC TESTING; HUMANS; PHARMACOGENETICS; POINT-OF-CARE SYSTEMS;

EID: 84871263743     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.196     Document Type: Article

References (5)

1. Voora, D. & Ginsburg, G.S. Clinical application of cardiovascular pharmacogenetics. J. Am. Coll. Cardiol. 60, 9-20 (2012).
2. Dobson, M.G., Galvin, P. & Barton, D.E. Emerging technologies for point-of-care genetic testing. Expert Rev. Mol. Diagn. 7, 359-370 (2007).
3. Roberts, J.D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-ofconcept trial. Lancet 379, 1705-1711 (2012).
4. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92, 87-95 (2012).
5. O'Donnell, P.H. et al. The 1200 patients project: Creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92, 446-449 (2012).